Boruide Pharmaceutical: BGM0504 Tablets Achieve Positive Results in Phase I Clinical Trial for Weight Loss Indication

MetaMuskRat · 2026-03-25T18:04:52+00:00

Brinova Pharmaceuticals announced positive Phase I clinical trial results for its independently developed BGM0504 tablet conducted in China and the United States, demonstrating good safety and preliminary efficacy. These results provide support for subsequent Phase II studies. BGM0504 is expected to become an once-daily oral obesity treatment medication.

MetaMuskRat

2026-03-25 18:04:52

Abstract generation in progress

People’s Financial News, March 24 — Borui Medicine (688166) announced on March 24 the data from its Phase I clinical trial of BGM0504 tablets for weight loss indications. Recently, the company’s wholly-owned subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. independently developed BGM0504 tablets, which achieved positive results in Phase I clinical trials for treating overweight/obesity in adult participants in China and the United States. Based on the good safety, tolerability, preliminary pharmacokinetics, and efficacy data obtained from these Phase I trials in the US and China, BGM0504 is supported as a potential once-daily oral treatment for overweight or obesity to continue into subsequent Phase II clinical studies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.